Challenging position as postdoctoral scientist incorporating skills in immunological research, drug design and development, and immunotherapy
|
|
Status: Thesis submitted awaiting supervising committee approval
Practical work of PhD research was conducted in the Pharmaceutical Product Design group, Fraunhofer IME Institute, in the ForSaTum funded project for the rapid development and in vivo testing of cancer targeted therapeutics.
Final grade: 93/100
Molecular Biochemistry program
Graduated with honors, cum laude
Researching targeting skin Dendritic cells with therapeutic antibodies to induce tolerance towards allergens.
investigated the role of different Immunological cell types in the induction of oral tolerance
Designed and purified synthetic Sphingolipids, and investigated their therapeutic potential in various disease models
2011-2013
2012-2013
2008-2010
PhD. Thesis
"EpCAM and CSPG4 scFv based cytolytic fusion proteins for the treatment of triple negative breast cancer"
work focused on generating and optimizing the design, expression system and purification of cancer Immunotherapeutics, and characterizing their anti tumor activity in cell lines and in vivo in mouse xenograft models
Master's Thesis
"IgG1B cell receptor promotes development of B cells in the Bone Marrow and confers extended survival in the periphery of chimeric mouse model"
work focused on characterizing and studying B cells signaling, survival and functionality ex vivo and in vivo in chimeric mouse models.
Laboratory Animals Research training. Certification to work with laboratory animals from the Technion Institute of Technology, and Stanford University.
Flow Cytometry training. training to work with BD FACSCalibur™ and BD LSRFORTESSA.
Confocal microscopy training. intensive course in confocal microscopy, working on Leica TCS SP5 microscope.
Cell and Molecular Biology Techniques: Bacterial cultures, human and mouse cell lines and primary cells, Immuno-assays, Cloning, PCR, RT-PCR, Drug Evaluation assays, Flow Cytometry, Microscopy.
Work with Laboratory Mice: tumor xenografts models, EAE, colitis model, Immunological studies with transgenic and chimeric mice models, in vivo live imaging.
Recombinant Proteins: Design and expression-Mammalian and Bacterial systems, Protein and antibody Purification.
Data Analysis and Documentation: statistical data analysis, sequence analysis (DNA and Protein). Work in BSL-2 and S2-GMP lab, documentation under the German Genetic Engineering Safety Regulations (GenTSV)
Computer Skills: Microsoft Office, CLC workbench, Gimp, GraphPad PRISM software, AIDA image analyzer, FlowJo, BD cell quest, BD FACS Diva, work with NCBI, Immgen and UniProt databases
1. Hristodorov D*, Amoury M*, et al. EpCAM-selective elimination of carcinoma cells by a novel MAP-based cytolytic fusion protein. Mol Cancer Ther. 2014 Sep;13(9):2194-202. PubMed PMID: 24980949.
* shared first authors
2. Reis BS, Lee K, Fanok MH, Mascaraque C, Amoury M, et al. Leptin receptor signaling in T cells is required for Th17 differentiation. J Immunol. 2015 Jun 1;194(11):5253-60. PubMed PMID: 25917102.
3. Amoury M, Blume T, et al. SNAP-tag based agents for preclinical in vitro imaging in malignant diseases. Curr Pharm Des. 2013;19(30):5429-36. PubMed PMID: 23431985.
4. Hussain AF, Amoury M, Barth S. SNAP-tag technology: a powerful tool for site specific conjugation of therapeutic and imaging agents. Curr Pharm Des. 2013;19(30):5437-42. Review. PubMed PMID: 23431986.
Submitted manuscripts (not published yet):
1. Manal Amoury, Stefan Barth et al. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model. (Submitted to Cancer letters)
2. Manal Amoury, Dirk Bauerschlag, Ahmad Fawzi Hussain et al. On demand activatable photoimmuno-theranostics for triple negative breast cancer cells diagnosis and treatment
(submitted to theranostics)
3. Manal Amoury, Radoslav Mladenov, Stefan Barth et al. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein. (Submitted to Int. J of Cancer, currently working on revisions)
Companies Worked For:
School Attended
Job Titles Held:
Degrees
Advertisement
